These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

332 related articles for article (PubMed ID: 26184694)

  • 1. Atherosclerosis following renal injury is ameliorated by pioglitazone and losartan via macrophage phenotype.
    Yamamoto S; Zhong J; Yancey PG; Zuo Y; Linton MF; Fazio S; Yang H; Narita I; Kon V
    Atherosclerosis; 2015 Sep; 242(1):56-64. PubMed ID: 26184694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Macrophage polarization by angiotensin II-type 1 receptor aggravates renal injury-acceleration of atherosclerosis.
    Yamamoto S; Yancey PG; Zuo Y; Ma LJ; Kaseda R; Fogo AB; Ichikawa I; Linton MF; Fazio S; Kon V
    Arterioscler Thromb Vasc Biol; 2011 Dec; 31(12):2856-64. PubMed ID: 21979434
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pioglitazone-Incorporated Nanoparticles Prevent Plaque Destabilization and Rupture by Regulating Monocyte/Macrophage Differentiation in ApoE-/- Mice.
    Nakashiro S; Matoba T; Umezu R; Koga J; Tokutome M; Katsuki S; Nakano K; Sunagawa K; Egashira K
    Arterioscler Thromb Vasc Biol; 2016 Mar; 36(3):491-500. PubMed ID: 26821947
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparison of angiotensin-(1-7), losartan and their combination on atherosclerotic plaque formation in apolipoprotein E knockout mice.
    Yang J; Sun Y; Dong M; Yang X; Meng X; Niu R; Guan J; Zhang Y; Zhang C
    Atherosclerosis; 2015 Jun; 240(2):544-9. PubMed ID: 25957120
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antiatherogenic effects of angiotensin receptor antagonism in mild renal dysfunction.
    Suganuma E; Zuo Y; Ayabe N; Ma J; Babaev VR; Linton MF; Fazio S; Ichikawa I; Fogo AB; Kon V
    J Am Soc Nephrol; 2006 Feb; 17(2):433-41. PubMed ID: 16371432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Renin-angiotensin system activation accelerates atherosclerosis in experimental renal failure by promoting endoplasmic reticulum stress-related inflammation.
    Yang J; Zhang X; Yu X; Tang W; Gan H
    Int J Mol Med; 2017 Mar; 39(3):613-621. PubMed ID: 28098884
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Periaortic adipose tissue-specific activation of the renin-angiotensin system contributes to atherosclerosis development in uninephrectomized apoE-/- mice.
    Kawahito H; Yamada H; Irie D; Kato T; Akakabe Y; Kishida S; Takata H; Wakana N; Ogata T; Ikeda K; Ueyama T; Matoba S; Mori Y; Matsubara H
    Am J Physiol Heart Circ Physiol; 2013 Sep; 305(5):H667-75. PubMed ID: 23812390
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.
    Hennuyer N; Tailleux A; Torpier G; Mezdour H; Fruchart JC; Staels B; Fiévet C
    Arterioscler Thromb Vasc Biol; 2005 Sep; 25(9):1897-902. PubMed ID: 15994444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamic changes of adiponectin and S100A8 levels by the selective peroxisome proliferator-activated receptor-gamma agonist rivoglitazone.
    Hiuge-Shimizu A; Maeda N; Hirata A; Nakatsuji H; Nakamura K; Okuno A; Kihara S; Funahashi T; Shimomura I
    Arterioscler Thromb Vasc Biol; 2011 Apr; 31(4):792-9. PubMed ID: 21233451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Losartan inhibits LPS-induced inflammatory signaling through a PPARgamma-dependent mechanism in human THP-1 macrophages.
    An J; Nakajima T; Kuba K; Kimura A
    Hypertens Res; 2010 Aug; 33(8):831-5. PubMed ID: 20505677
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pioglitazone suppresses macrophage proliferation in apolipoprotein-E deficient mice by activating PPARγ.
    Murakami-Nishida S; Matsumura T; Senokuchi T; Ishii N; Kinoshita H; Yamada S; Morita Y; Nishida S; Motoshima H; Kondo T; Komohara Y; Araki E
    Atherosclerosis; 2019 Jul; 286():30-39. PubMed ID: 31096071
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pioglitazone suppresses inflammation in vivo in murine carotid atherosclerosis: novel detection by dual-target fluorescence molecular imaging.
    Chang K; Francis SA; Aikawa E; Figueiredo JL; Kohler RH; McCarthy JR; Weissleder R; Plutzky J; Jaffer FA
    Arterioscler Thromb Vasc Biol; 2010 Oct; 30(10):1933-9. PubMed ID: 20689078
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Poly(ADP-ribose) polymerase inhibition reduces atherosclerotic plaque size and promotes factors of plaque stability in apolipoprotein E-deficient mice: effects on macrophage recruitment, nuclear factor-kappaB nuclear translocation, and foam cell death.
    Oumouna-Benachour K; Hans CP; Suzuki Y; Naura A; Datta R; Belmadani S; Fallon K; Woods C; Boulares AH
    Circulation; 2007 May; 115(18):2442-50. PubMed ID: 17438151
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of macrophage-dependent peroxisome proliferator-activated receptor γ signalling on adhesion formation after abdominal surgery in an experimental model.
    Hong GS; Schwandt T; Stein K; Schneiker B; Kummer MP; Heneka MT; Kitamura K; Kalff JC; Wehner S
    Br J Surg; 2015 Nov; 102(12):1506-16. PubMed ID: 26313905
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An apoptotic body-biomimic liposome in situ upregulates anti-inflammatory macrophages for stabilization of atherosclerotic plaques.
    Wu Y; Zhang Y; Dai L; Wang Q; Xue L; Su Z; Zhang C
    J Control Release; 2019 Dec; 316():236-249. PubMed ID: 31672624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Aldosterone administration to mice stimulates macrophage NADPH oxidase and increases atherosclerosis development: a possible role for angiotensin-converting enzyme and the receptors for angiotensin II and aldosterone.
    Keidar S; Kaplan M; Pavlotzky E; Coleman R; Hayek T; Hamoud S; Aviram M
    Circulation; 2004 May; 109(18):2213-20. PubMed ID: 15123520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of combination PPARγ agonist and angiotensin receptor blocker on glomerulosclerosis.
    Matsushita K; Yang HC; Mysore MM; Zhong J; Shyr Y; Ma LJ; Fogo AB
    Lab Invest; 2016 Jun; 96(6):602-9. PubMed ID: 26999660
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Additive effect of PPAR-γ agonist and ARB in treatment of experimental IgA nephropathy.
    Lai KN; Chan LY; Guo H; Tang SC; Leung JC
    Pediatr Nephrol; 2011 Feb; 26(2):257-66. PubMed ID: 21125406
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of new thiazolidine derivatives LPSF/GQ-02 and LPSF/GQ-16 on atherosclerotic lesions in LDL receptor-deficient mice (LDLR(-/-)).
    Soares E Silva AK; de Oliveira Cipriano Torres D; Santos Rocha SW; dos Santos Gomes FO; dos Santos Silva B; Donato MA; Raposo C; Santos AC; de Lima Mdo C; Galdino SL; da Rocha Pitta I; de Souza JR; Peixoto CA
    Cardiovasc Pathol; 2013; 22(1):81-90. PubMed ID: 22795892
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pioglitazone increases macrophage apoptosis and plaque necrosis in advanced atherosclerotic lesions of nondiabetic low-density lipoprotein receptor-null mice.
    Thorp E; Kuriakose G; Shah YM; Gonzalez FJ; Tabas I
    Circulation; 2007 Nov; 116(19):2182-90. PubMed ID: 17967777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.